NeoGenomics, Inc. Stock price

Equities

NEO

US64049M2098

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
15.72 USD +3.42% Intraday chart for NeoGenomics, Inc. +1.81% -2.84%
Sales 2024 * 655M Sales 2025 * 718M Capitalization 2.01B
Net income 2024 * -72M Net income 2025 * -51M EV / Sales 2024 * 3.5 x
Net Debt 2024 * 286M Net Debt 2025 * 272M EV / Sales 2025 * 3.17 x
P/E ratio 2024 *
-27.6 x
P/E ratio 2025 *
-40 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.42%
1 week+1.16%
Current month+0.77%
1 month-2.54%
3 months-23.32%
6 months+26.57%
Current year-2.84%
More quotes
1 week
14.75
Extreme 14.75
15.91
1 month
14.30
Extreme 14.3
16.34
Current year
13.77
Extreme 13.77
17.49
1 year
11.03
Extreme 11.03
21.22
3 years
6.00
Extreme 6
54.74
5 years
6.00
Extreme 6
61.57
10 years
2.95
Extreme 2.95
61.57
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 22-08-14
Chairman 61 15-06-11
Director of Finance/CFO 58 22-12-06
Members of the board TitleAgeSince
Director/Board Member 72 14-10-21
Director/Board Member 67 20-07-14
Chief Executive Officer 61 22-08-14
More insiders
Date Price Change Volume
24-03-28 15.72 +3.42% 654,428
24-03-27 15.2 +0.26% 787,191
24-03-26 15.16 +2.71% 808,742
24-03-25 14.76 -2.96% 613,629
24-03-22 15.21 -1.49% 639,911

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
15.72 USD
Average target price
21.55 USD
Spread / Average Target
+37.06%
Consensus
  1. Stock
  2. Equities
  3. Stock NeoGenomics, Inc. - Nasdaq